Asianet Newsable on MSN

How Abivax went from biotech nobody to M&A bullseye after a single blockbuster readout this year

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.

How the ‘Ford philosophy’ produced English rugby’s deepest thinkers

George, his two brothers and dad Mike discuss the family dynasty, coaching plans and mum’s vain hope of a Christmas with no ...